Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug836 | Canakinumab Injection 300mg Wiki | 1.00 |
| drug2477 | NICU Acquires MOM Wiki | 1.00 |
| drug837 | Canakinumab Injection 600mg Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
In the US, the burden of very low birth weight (VLBW; <1500 g) birth is borne disproportionately by black (non-Hispanic black/African American) mothers who are 2.2-2.6 times more likely than nonblack mothers to deliver VLBW infants. This disparity is amplified because black VLBW infants are significantly less likely to receive mother's own milk (MOM) feedings from birth until neonatal intensive care unit (NICU) discharge than nonblack infants, which adds to the lifelong burden of VLBW birth with increased risk of morbidities and greater costs. Pumping is associated with out-of-pocket and opportunity costs that are borne by mothers, unlike donor human milk and formula, which are paid for by NICUs. This innovative trial will determine the effectiveness of the intervention in reducing the disparity in MOM feedings and provide an economic analysis of the interventions, yielding critical data impacting generalizability and likelihood of implementation of results. The investigators hypothesize that mothers who receive intervention will have greater pumping volume and duration and their infants will be more likely to receive MOM at NICU discharge compared to mothers who receive standard of care lactation care and their infants.
Description: Determined from the last full day of hospitalization and categorized as "Yes" if the infant received any or exclusive MOM and "No" if the infant received only formula.
Measure: Receipt of MOM at NICU Discharge Time: Through study completion, an average of 10 weeksDescription: Determined from the entire hospitalization and categorized as "Yes" if the infant received any or exclusive MOM and "No" if the never received MOM during the hospitalization.
Measure: Receipt of any MOM Time: Through study completion, an average of 10 weeksDescription: Determined from the entire hospitalization and calculated as the number of days infant received any MOM.
Measure: Duration of MOM feedings Time: Through study completion, an average of 10 weeksDescription: Determined from the entire hospitalization and calculated as the total volume of MOM received by the infant.
Measure: Cumulative dose of MOM feedings Time: Through study completion, an average of 10 weeksDescription: Determined from the entire hospitalization and calculated as the number of days mother pumped MOM.
Measure: Duration of MOM pumped Time: Through study completion, an average of 10 weeksDescription: Determined from the entire hospitalization and calculated as the total volume of MOM pumped by the mother.
Measure: Volume of MOM pumped Time: Through study completion, an average of 10 weeksDescription: Costs borne by healthcare providers or third-party payers, including the cost of the hospital stay and donor human milk and formula costs.
Measure: Healthcare system costs Time: Through study completion, an average of 10 weeksDescription: Participant costs will be measured in dollars and will be the sum of opportunity costs (i.e., mother's time spent pumping (mothers in control group only), time off work to visit NICU), caregiving costs for other children or adults when mother or partner visits the NICU, transportation costs, lodging costs, and other out-of-pocket costs
Measure: Participant costs in US Dollars Time: Through study completion, an average of 10 weeksDescription: The costs of the intervention including milk pick-up, free provision of pumps, and opportunity costs payments for the intervention arm.
Measure: ReDiMOM Intervention Costs in US Dollars Time: Through study completion, an average of 10 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports